INTRODUCTION: Inflammatory skin diseases can be examined from many viewpoints. In this review, we consider three distinct cutaneous inflammatory diseases from the point of view of their major lesional dendritic cell (DC) subpopulations. The DC populations considered are Langerhans cells, myeloid DCs, and plasmacytoid DCs (pDCs), with specific attention to the presence and role of the inflammatory counterparts of these cells. From such a "dendritic cell-centric" focus, psoriasis, atopic dermatitis (AD), and cutaneous lupus erythematosus (CLE) are explored. DISCUSSION: In psoriasis, there is a specific population of myeloid "inflammatory" DCs that appears to play an important pathogenic role, while pDCs have been recently implicated in the initiation of psoriatic lesions. In AD, Langerhans cells may be important during initiation, while "inflammatory dendritic epidermal cells" (IDECs) appear to be abundant in lesional epidermis and dermis and contribute to maintenance of AD. These IDECs may actually be analogous to the myeloid inflammatory DCs found in the epidermal and dermal compartments of the skin in psoriasis, although they express distinct surface markers and induce different T cell polarities as a result of different cytokine milieu in which they develop. CLE has been recently characterized as a type I IFN-mediated disease, and pDCs are integral to the pathogenesis of this disease. CONCLUSION: Thus, these DC subpopulations and their products will be reviewed in the context of these three cutaneous diseases to provide clinico-pathophysiological correlations between the lesional DCs, their products, and the skin diseases.
INTRODUCTION:Inflammatory skin diseases can be examined from many viewpoints. In this review, we consider three distinct cutaneous inflammatory diseases from the point of view of their major lesional dendritic cell (DC) subpopulations. The DC populations considered are Langerhans cells, myeloid DCs, and plasmacytoid DCs (pDCs), with specific attention to the presence and role of the inflammatory counterparts of these cells. From such a "dendritic cell-centric" focus, psoriasis, atopic dermatitis (AD), and cutaneous lupus erythematosus (CLE) are explored. DISCUSSION: In psoriasis, there is a specific population of myeloid "inflammatory" DCs that appears to play an important pathogenic role, while pDCs have been recently implicated in the initiation of psoriatic lesions. In AD, Langerhans cells may be important during initiation, while "inflammatory dendritic epidermal cells" (IDECs) appear to be abundant in lesional epidermis and dermis and contribute to maintenance of AD. These IDECs may actually be analogous to the myeloid inflammatory DCs found in the epidermal and dermal compartments of the skin in psoriasis, although they express distinct surface markers and induce different T cell polarities as a result of different cytokine milieu in which they develop. CLE has been recently characterized as a type I IFN-mediated disease, and pDCs are integral to the pathogenesis of this disease. CONCLUSION: Thus, these DC subpopulations and their products will be reviewed in the context of these three cutaneous diseases to provide clinico-pathophysiological correlations between the lesional DCs, their products, and the skin diseases.
Authors: Eva V Acosta-Rodriguez; Giorgio Napolitani; Antonio Lanzavecchia; Federica Sallusto Journal: Nat Immunol Date: 2007-08-05 Impact factor: 25.606
Authors: Michelle A Lowes; Toyoko Kikuchi; Judilyn Fuentes-Duculan; Irma Cardinale; Lisa C Zaba; Asifa S Haider; Edward P Bowman; James G Krueger Journal: J Invest Dermatol Date: 2008-01-17 Impact factor: 8.551
Authors: Lisa C Zaba; Judilyn Fuentes-Duculan; Ralph M Steinman; James G Krueger; Michelle A Lowes Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Francesca Capon; Paola Di Meglio; Joanna Szaub; Natalie J Prescott; Christina Dunster; Laura Baumber; Kirsten Timms; Alexander Gutin; Victor Abkevic; A David Burden; Jerry Lanchbury; Jonathan N Barker; Richard C Trembath; Frank O Nestle Journal: Hum Genet Date: 2007-06-22 Impact factor: 4.132
Authors: Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger Journal: J Exp Med Date: 2007-11-26 Impact factor: 14.307
Authors: A Chiricozzi; M Suárez-Fariñas; J Fuentes-Duculan; I Cueto; K Li; S Tian; C Brodmerkel; J G Krueger Journal: Br J Dermatol Date: 2015-11-11 Impact factor: 9.302
Authors: Hideki Fujita; Kristine E Nograles; Toyoko Kikuchi; Juana Gonzalez; John A Carucci; James G Krueger Journal: Proc Natl Acad Sci U S A Date: 2009-12-08 Impact factor: 11.205
Authors: Michelle A Lowes; Chris B Russell; David A Martin; Jennifer E Towne; James G Krueger Journal: Trends Immunol Date: 2013-01-03 Impact factor: 16.687
Authors: K Masek-Hammerman; E Peeva; A Ahmad; S Menon; M Afsharvand; R Peng Qu; J B Cheng; J Syed; Y Zhan; S P O'Neil; S Pleasic-Williams; L A Cox; D Beidler Journal: Clin Exp Immunol Date: 2015-11-09 Impact factor: 4.330
Authors: Douglas A Plager; Jane C Kahl; Yan W Asmann; Allan E Nilson; John F Pallanch; Oren Friedman; Hirohito Kita Journal: PLoS One Date: 2010-07-06 Impact factor: 3.240